Proteomic Biomarker Discovery in Cerebrospinal Fluid for MS and NMO Differentiation

A proteomic analysis of cerebrospinal fluid from patients with multiple sclerosis and neuromyelitis optica, identifying 3,816 proteins. The dataset was published by Mengyang Ding on figshare in April 2026. It includes validation results for CD74 and CD14 as potential disease-specific biomarkers.

Use Cases

• Training classification models to differentiate MS from NMO based on proteomic signatures.
• Validating potential protein biomarkers like CD74 and CD14 using independent cohort data.
• Analyzing disease-specific molecular pathways such as glycosylation in MS or hemostasis in NMO.
• Investigating low-abundance protein enrichment strategies for biomarker discovery in CSF.

Strengths

• Deep proteome coverage of 3,816 proteins identified in cerebrospinal fluid.
• Includes validation in an independent cohort with reported AUC scores (0.75 for CD74, 0.72 for CD14).
• Employs a nanoparticle-based low-abundance protein enrichment strategy to expand protein detection.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small in size (310.0 KB), indicating a limited scope of raw or summary data.

Provenance

Source

figshare

Collection Method

Comprehensive proteomic analysis of CSF using conventional proteomics and a nanoparticle-based enrichment strategy (LAPE), validated by ELISA.

Time Range

null

Freshness

Last updated 2026-04-30 14:34:32; freshness should be verified.

Geography

null